RU2002130200A - Композиции для доставки лекарственного средства - Google Patents
Композиции для доставки лекарственного средстваInfo
- Publication number
- RU2002130200A RU2002130200A RU2002130200/15A RU2002130200A RU2002130200A RU 2002130200 A RU2002130200 A RU 2002130200A RU 2002130200/15 A RU2002130200/15 A RU 2002130200/15A RU 2002130200 A RU2002130200 A RU 2002130200A RU 2002130200 A RU2002130200 A RU 2002130200A
- Authority
- RU
- Russia
- Prior art keywords
- polynucleotide
- composition according
- specified
- composition
- histone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102100039869 Histone H2B type F-S Human genes 0.000 claims 4
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229960003677 chloroquine Drugs 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Claims (8)
1. Композиция, содержащая конъюгат полинуклеотида и гистонового белка или фрагмента указанного белка, который сохраняет способность связываться с полинуклеотидом и подвергаться трансфекции, причем, указанная композиция не содержит сыворотки, ионов кальция, хлорохина и катионных липидов и предназначена для терапевтического применения.
2. Композиция по п.1, где указанным гистоновым белком является гистон H1.
3. Композиция, содержащая гистоновый белок, включающий в себя аминокислотную последовательность, определяемую здесь как SEQ ID NO:2, и полинуклеотид.
4. Композиция по п.3, где указанным полинуклеотидом является ДНК.
5. Композиция по п.3, где указанным полинуклеотидом является РНК.
6. Композиция по любому из пп.3-5 для терапевтического применения.
7. Гистоновый белок для трансфекции полинуклеотида, состоящий из аминокислотной последовательности SEQ ID NO:2.
8. Композиция по любому из пп.1-6 в качестве активного ингредиента для изготовления лекарственного средства для внутримышечного или внутрикожного введения для лечения заболевания.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0009080.3 | 2000-04-12 | ||
GB0009080A GB0009080D0 (en) | 2000-04-12 | 2000-04-12 | Drug delivery |
GB0102667A GB0102667D0 (en) | 2001-02-02 | 2001-02-02 | Drug delivery |
GB0102667.3 | 2001-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002130200A true RU2002130200A (ru) | 2004-03-27 |
Family
ID=26244096
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002130200/15A RU2002130200A (ru) | 2000-04-12 | 2001-04-12 | Композиции для доставки лекарственного средства |
RU2002130203/15A RU2002130203A (ru) | 2000-04-12 | 2001-04-12 | Пептидные конъюгаты для доставки лекарственного средства |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002130203/15A RU2002130203A (ru) | 2000-04-12 | 2001-04-12 | Пептидные конъюгаты для доставки лекарственного средства |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040110928A1 (ru) |
EP (2) | EP1272221A2 (ru) |
JP (2) | JP2004528266A (ru) |
AU (2) | AU4674101A (ru) |
CA (2) | CA2406233A1 (ru) |
IL (2) | IL151910A0 (ru) |
NZ (2) | NZ521563A (ru) |
RU (2) | RU2002130200A (ru) |
WO (2) | WO2001076637A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2640247C2 (ru) * | 2007-04-05 | 2017-12-27 | Зюмбиотек Гезелльшафт Цур Форшунг Унд Энтвиклунг Ауф Дем Гебит Дер Биотехнологи Мбх | БИС-Met-ГИСТОНЫ |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ521563A (en) * | 2000-04-12 | 2004-05-28 | Implyx Ltd | Peptide conjugates for drug delivery |
GB0116047D0 (en) * | 2001-06-29 | 2001-08-22 | Implyx Ltd | Peptide motif for therapy |
WO2005068616A2 (en) * | 2004-01-16 | 2005-07-28 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Immunokinases |
WO2005117991A2 (en) * | 2004-05-04 | 2005-12-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
US7659289B2 (en) * | 2004-09-17 | 2010-02-09 | Comentis, Inc. | Hydroxyethylene-based β-secretase inhibitors and use thereof |
CA2580238A1 (en) * | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
BRPI0607019A2 (pt) * | 2005-04-08 | 2009-07-28 | Univ Illinois | compostos que inibem a atividade de beta -secretase e métodos de uso dos mesmos |
GB0507598D0 (en) | 2005-04-14 | 2005-05-18 | Trojantec Technologies Ltd | Composition |
WO2007017212A2 (de) * | 2005-08-05 | 2007-02-15 | Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh | Verwendung eines biologischen wirkstoffes bei abnormalen zellulären und viralen membranphysiologien |
WO2007020886A1 (ja) | 2005-08-16 | 2007-02-22 | Sanyo Chemical Industries, Ltd. | タンパク質のリフォールディング剤およびリフォールディング方法 |
JP4625433B2 (ja) * | 2005-08-16 | 2011-02-02 | 三洋化成工業株式会社 | タンパク質のリフォールディング剤およびリフォールディング方法 |
EP1942943A2 (en) * | 2005-11-04 | 2008-07-16 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
EP1800695A1 (en) * | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
AU2007256780B2 (en) | 2006-06-02 | 2013-08-29 | President And Fellows Of Harvard College | Protein surface remodeling |
WO2009013359A2 (en) * | 2007-07-25 | 2009-01-29 | Fraunhofer Gesellschaft Zur Förderung Der Angewandten Forschung E. V. | Self coupling recombinant antibody fusion proteins |
MX2010000956A (es) * | 2007-07-26 | 2010-03-01 | Comentis Inc | Derivados de isoftalamida que inhiben actividad de beta-secretasa. |
CN101868457B (zh) * | 2007-09-24 | 2013-02-13 | 科门蒂斯公司 | 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物 |
CN102066405B (zh) * | 2008-04-28 | 2015-09-30 | 哈佛大学校长及研究员协会 | 用于细胞穿透的超荷电蛋白 |
WO2010129023A2 (en) | 2009-04-28 | 2010-11-11 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE256148C (ru) * | ||||
US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
DE4005152A1 (de) * | 1990-02-17 | 1991-08-22 | Guenter Prof Dr Kahl | Verbesserung der transformation von pflanzenzellen |
CA2090355C (en) * | 1993-02-25 | 1997-04-08 | Jian Chen | Method of gene transfer using galactosylated histones |
GB9422495D0 (en) * | 1994-11-08 | 1995-01-04 | Medical Res Council | DNA transfer method |
FR2730637B1 (fr) * | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
JP2002514892A (ja) * | 1995-06-08 | 2002-05-21 | コブラ セラピューティクス リミテッド | 遺伝子治療における合成ウイルス様粒子の使用 |
US5744335A (en) * | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
GB9718609D0 (en) * | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
EP0967288A1 (en) * | 1998-06-16 | 1999-12-29 | Hoechst Marion Roussel Deutschland GmbH | Transfection system for the transfer of nucleic acids into cells |
EP0908521A1 (en) * | 1997-10-10 | 1999-04-14 | Hoechst Marion Roussel Deutschland GmbH | Transfection system for the transfer of nucleic acids into cells |
NZ521563A (en) * | 2000-04-12 | 2004-05-28 | Implyx Ltd | Peptide conjugates for drug delivery |
-
2001
- 2001-04-12 NZ NZ521563A patent/NZ521563A/en unknown
- 2001-04-12 RU RU2002130200/15A patent/RU2002130200A/ru unknown
- 2001-04-12 WO PCT/GB2001/001697 patent/WO2001076637A2/en not_active Application Discontinuation
- 2001-04-12 JP JP2001574153A patent/JP2004528266A/ja active Pending
- 2001-04-12 EP EP01919679A patent/EP1272221A2/en not_active Withdrawn
- 2001-04-12 CA CA002406233A patent/CA2406233A1/en not_active Abandoned
- 2001-04-12 AU AU46741/01A patent/AU4674101A/en not_active Abandoned
- 2001-04-12 US US10/240,430 patent/US20040110928A1/en not_active Abandoned
- 2001-04-12 WO PCT/GB2001/001699 patent/WO2001076638A2/en active IP Right Grant
- 2001-04-12 CA CA002406352A patent/CA2406352A1/en not_active Abandoned
- 2001-04-12 IL IL15191001A patent/IL151910A0/xx unknown
- 2001-04-12 JP JP2001574152A patent/JP2003530360A/ja active Pending
- 2001-04-12 RU RU2002130203/15A patent/RU2002130203A/ru unknown
- 2001-04-12 AU AU46739/01A patent/AU4673901A/en not_active Abandoned
- 2001-04-12 NZ NZ521564A patent/NZ521564A/en unknown
- 2001-04-12 IL IL15190901A patent/IL151909A0/xx unknown
- 2001-04-12 EP EP01919681A patent/EP1272222A2/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2640247C2 (ru) * | 2007-04-05 | 2017-12-27 | Зюмбиотек Гезелльшафт Цур Форшунг Унд Энтвиклунг Ауф Дем Гебит Дер Биотехнологи Мбх | БИС-Met-ГИСТОНЫ |
Also Published As
Publication number | Publication date |
---|---|
WO2001076638A3 (en) | 2002-05-16 |
WO2001076638A2 (en) | 2001-10-18 |
WO2001076637A3 (en) | 2002-05-23 |
RU2002130203A (ru) | 2004-03-27 |
IL151910A0 (en) | 2003-04-10 |
AU4674101A (en) | 2001-10-23 |
CA2406352A1 (en) | 2001-10-18 |
JP2004528266A (ja) | 2004-09-16 |
US20040110928A1 (en) | 2004-06-10 |
NZ521564A (en) | 2004-06-25 |
JP2003530360A (ja) | 2003-10-14 |
IL151909A0 (en) | 2003-04-10 |
NZ521563A (en) | 2004-05-28 |
EP1272222A2 (en) | 2003-01-08 |
CA2406233A1 (en) | 2001-10-18 |
EP1272221A2 (en) | 2003-01-08 |
AU4673901A (en) | 2001-10-23 |
WO2001076637A2 (en) | 2001-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002130200A (ru) | Композиции для доставки лекарственного средства | |
RU2468080C2 (ru) | Новый класс терапевтических белковых молекул | |
JP6406793B2 (ja) | トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド(iro)化合物 | |
BR0212897A (pt) | Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos | |
BR9915919A (pt) | Proteìnas terapeuticamente ativas em plantas | |
JP2012505221A (ja) | 高コレステロール血症および高脂血症ならびにそれらに関連する疾患の予防および処置におけるトル様受容体の阻害剤の使用 | |
RU2000124084A (ru) | Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты) | |
EP1975235A3 (en) | Porcine circovirus vaccine in recombinant poxvirus | |
JP2006512300A5 (ru) | ||
PT1511845E (pt) | Oligonucleótidos imuno-estimuladores e suas utilizações | |
US10041076B2 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
RU98120519A (ru) | Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний | |
DE50010519D1 (de) | Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz | |
WO2001098522A3 (en) | Positively-charged peptide nucleic acid analogs with improved properties | |
ZA9610840B (en) | Novel binding agents and the use thereof | |
Gray et al. | B/PI-derived synthetic peptides: synergistic effects in tethered bactericidal and endotoxin neutralizing peptides | |
BR9809457A (pt) | Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia. | |
JP2005508875A5 (ru) | ||
US20130225479A1 (en) | Methods and Compositions for Treating Inflammation | |
US7879812B2 (en) | Immunomodulatory oligonucleotides and methods of use therefor | |
WO2007024029A1 (en) | Antiviral agent and viral replication inhibitor | |
RU2440369C2 (ru) | ГЕНЫ И БЕЛКИ Brachyspira hyodysenteriae И ИХ ПРИМЕНЕНИЕ | |
CA2250433A1 (en) | Human dnase ii | |
DK0811068T3 (da) | Humane DNase I varianter | |
WO2000026362A3 (de) | Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie |